期刊
MOLECULAR THERAPY-NUCLEIC ACIDS
卷 19, 期 -, 页码 581-601出版社
CELL PRESS
DOI: 10.1016/j.omtn.2019.12.004
关键词
-
资金
- National Natural Science Foundation of China [31871003, 31901053]
- Fundamental Research Funds for the Central Universities, China
- Beijing Institute of Technology Research Fund Program for Young Scholars, China
- Hunan Provincial Natural Science Foundation of China [2018JJ1019, 2019JJ50196]
- Postdoctoral Science Foundation of China [2018M630085]
- Hu-Xiang Young Talent Program [2018RS3094]
Due to a series of systemic and intracellular obstacles in nucleic acid (NA) therapy, including fast degradation in blood, renal clearance, poor cellular uptake, and inefficient endosomal escape, NAs may need delivery methods to transport to the cell nucleus or cytosol to be effective. Advanced nanoscale biotechnology-associated strategies, such as controlling the particle size, charge, drug loading, response to environmental signals, or other physical/chemical properties of delivery carriers, have provided great help for the in vivo and in vitro delivery of NA therapeutics. In this review, we introduce the characteristics of different NA modalities and illustrate how advanced nanoscale biotechnology assists NA therapy. The specific features and challenges of various nanocarriers in clinical and preclinical studies are summarized and discussed. With the help of advanced nanoscale biotechnology, some of the major barriers to the development of NA therapy will eventually be overcome in the near future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据